A Phase I/II, Open Label, Multi-Center Study For The Evaluation Of CPG 7909 [Agatolimod] In Patients With Stage Iv Renal Cell Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 13 Jan 2009
At a glance
- Drugs Agatolimod (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 13 Jan 2009 Official title updated from ClinicalTrials.gov record. Actual end date reported as September 2004; actual patient number is 42.
- 20 Jun 2007 Pfizer has discontinued the PF-3512676 development programme because of no evidence of additional clinical efficacy compared with standard antineoplastics alone.
- 07 Aug 2006 Status change